SCHEMBL584588

SCHEMBL584588

Ic1nccn1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.43
CYP11B2 P19099 3/20 0.43
KMT2A Q03164 3/20 0.42
KCNN4 O15554 2/20 0.36
KCNA3 P22001 2/20 0.36
MEN1 O00255 2/20 0.36
TSHR P16473 2/20 0.35
NR1I2 O75469 2/20 0.35
ADORA3 P0DMS8 2/20 0.35
TBXA2R P21731 2/20 0.35
CCKBR P32239 2/20 0.35
OPRK1 P41145 2/20 0.35
SLC6A3 Q01959 2/20 0.35
KCNH2 Q12809 2/20 0.35
NR1H4 Q96RI1 2/20 0.35
CHRM2 P08172 2/20 0.35
SLC22A1 O15245 1/20 0.35
GMNN O75496 1/20 0.35
USP2 O75604 1/20 0.35
TRPM2 O94759 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5240188 0.77 CYP11B1 (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL392779 0.77 CYP11B1 (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL10915007 0.77 CYP11B1 (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL4543871 0.77 CYP11B1 (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL27685085 0.77 CYP11B1 (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL2279828 0.77 CYP11B1 (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL6467815 0.77 KMT2A (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL1532332 0.74 CYP11B1 (0.41) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL6948425 0.73 KMT2A (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3
SCHEMBL1845371 0.73 KMT2A (0.43) CYP11B1CYP11B2KMT2AKCNN4KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435061-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2025-10-07 US disclosed
EP-4574822-A2 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2025-06-25 EP disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
CN-118702672-A Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-09-27 CN disclosed
US-11999716-B2 WDR5 inhibitors and modulators VANDERBILT UNIVERSITY (US) 2024-06-04 US disclosed
CN-115335050-B Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-05-17 CN disclosed
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2024-04-18 US disclosed
EP-4055013-B1 WDR5 INHIBITORS AND MODULATORS UNIV VANDERBILT (US) 2024-03-20 EP disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 US disclosed
EP-2125823-B1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-02-15 EP disclosed
EP-2125823-B1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-02-15 EP disclosed
CN-101248078-B Fused imidazole derivatives for inhibiting aldosterone synthase and aromatase NOVARTIS AG 2012-01-04 CN disclosed
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-15 US disclosed
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-15 US disclosed
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-15 US disclosed
US-20100016610-A1 FRICTIONLESS MOLECULAR ROTARY MOTORS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2010-01-21 US disclosed
CN-101568542-A 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives ACTELION PHARMACEUTICALS LTD (CH) 2009-10-28 CN disclosed
WO-2008096360-A2 FRICTIONLESS MOLECULAR ROTARY MOTORS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2008-08-14 WO disclosed
WO-2008078291-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435061-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 CYP11B1 796/4885CYP11B2 786/4885KMT2A 1859/4885
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES HCRTR1, HCRTR2, NPY5R CYP11B1 336/4885CYP11B2 338/4885KMT2A 1613/4885
US-11999716-B2 WDR5 inhibitors and modulators WDR5, WDR1, WDR3 CYP11B1 4316/4885CYP11B2 4456/4885KMT2A 558/4885
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 CYP11B1 796/4885CYP11B2 786/4885KMT2A 1859/4885
US-20100016610-A1 FRICTIONLESS MOLECULAR ROTARY MOTORS DYNLL2, ATXN2L, DYNLL1 CYP11B1 4160/4885CYP11B2 4163/4885KMT2A 1032/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 CYP11B1 4665/4885CYP11B2 4550/4885KMT2A 3415/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 CYP11B1 796/4885CYP11B2 786/4885KMT2A 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.